Datasets:
id int64 1.17M 2.23M | trial_nct_id stringlengths 11 11 | description stringlengths 1 300 ⌀ | label stringlengths 1 101 | type stringclasses 6
values |
|---|---|---|---|---|
1,173,743 | NCT07169825 | null | Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA | EXPERIMENTAL |
1,173,744 | NCT01153542 | null | VX-770 | EXPERIMENTAL |
1,173,745 | NCT01153542 | null | desipramine | EXPERIMENTAL |
1,173,746 | NCT03169374 | Virtual Reality Therapy | Virtual Reality Technology | EXPERIMENTAL |
1,173,747 | NCT02730169 | BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules) | BGS649 0.1 mg | EXPERIMENTAL |
1,173,748 | NCT02730169 | BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules) | BGS649 0.3 mg | EXPERIMENTAL |
1,173,749 | NCT02730169 | BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules) | BGS649 1.0 mg | EXPERIMENTAL |
1,173,750 | NCT02730169 | Placebo weekly (3 indistinguishable placebo capsules) | Placebo | PLACEBO_COMPARATOR |
1,173,751 | NCT03885206 | Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual. | Hospital | EXPERIMENTAL |
1,173,752 | NCT03885206 | Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician. | Municipal acute ward | NO_INTERVENTION |
1,173,753 | NCT03076164 | Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily. | Trametinib 1.5mg + Erlotinib 75mg | EXPERIMENTAL |
1,173,754 | NCT04250844 | We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functi | Botulinum | null |
1,173,755 | NCT04250844 | We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections. | Control | null |
1,173,756 | NCT01100580 | "The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)." | water therapy | ACTIVE_COMPARATOR |
1,173,757 | NCT01100580 | low salt diet refers to a salt intake of 4 g/day | low salt diet + water therapy | EXPERIMENTAL |
1,173,758 | NCT02571881 | Oxycodone 10 mg prolonged release tablet twice a day after caesarean section | Oxycodone | ACTIVE_COMPARATOR |
1,173,759 | NCT02571881 | Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section | Oxycodone-naloxone | EXPERIMENTAL |
1,173,760 | NCT03796130 | "This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months | (A)Myomectomy | EXPERIMENTAL |
1,173,761 | NCT03796130 | "This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy" | (B) No myomectomy | NO_INTERVENTION |
1,173,762 | NCT04574505 | 1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks | NUT | EXPERIMENTAL |
1,173,763 | NCT04574505 | 1 tablet of Placebo per day + standard diet for 8 weeks | Placebo | PLACEBO_COMPARATOR |
1,173,764 | NCT02117154 | 6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart | HbA1c, 6-day Professional CGM | null |
1,173,765 | NCT01622335 | General anesthesia and Air | General anesthesia with oxygen | PLACEBO_COMPARATOR |
1,173,766 | NCT01622335 | General anesthesia with Nitrous Oxide | nitrous oxide and general anesthesia | EXPERIMENTAL |
1,173,767 | NCT06833801 | Participants in this group will receive an optimized intelligent care system designed to enhance patient safety, improve treatment adherence, and reduce anxiety during radiation therapy. This system includes real-time blood data monitoring alerts, enhanced patient education materials, and internal w | Intelligent Care System Group (Intervention Group) | EXPERIMENTAL |
1,173,768 | NCT06348212 | They are given probiotic capsules of Lactobacillus paracasei PS23. Each capsule contains 100 mg of probiotic powder(10,000,000,000 CFU) Subjects should take two capsules per day for two months | Probiotic group | EXPERIMENTAL |
1,173,769 | NCT06348212 | They are given probiotic capsules of microcrystalline cellulose. Subjects should take two capsules per day for two months | Placebo group | PLACEBO_COMPARATOR |
1,173,770 | NCT05826158 | null | Children with Neuroblastoma | OTHER |
1,173,771 | NCT05504083 | take D-0120 dose 1 orally during the treatment period. | D-0120 group 1 | EXPERIMENTAL |
1,173,772 | NCT05504083 | take D-0120 dose 2 orally during the treatment period. | D-0120 group 2 | EXPERIMENTAL |
1,173,773 | NCT05504083 | take benzbromarone orally during the treatment period. | Benzbromarone | ACTIVE_COMPARATOR |
1,173,774 | NCT06833801 | Participants in this group will receive standard care without the optimized intelligent care system interventions. They will continue their treatment following existing clinical practices without additional automated monitoring or enhanced education strategies. | Standard Care Group (Control Group) | NO_INTERVENTION |
1,173,775 | NCT06787885 | Tavanic (levofloxacin )and dalacin (clindamycin) | Patient with empyema | OTHER |
1,173,776 | NCT06787885 | Tavanic (levofloxacin) and cefipime | Empyema patient | OTHER |
1,173,777 | NCT06787885 | Moxiflox (moxifloxacin) and meronem | patient has lung empyema | OTHER |
1,173,778 | NCT03842826 | Male athletes performing sports ≥ 1x/week Age: 18-40 years | Athlete | null |
1,173,779 | NCT06778148 | Providers assigned a license | Assigned Abridge license | EXPERIMENTAL |
1,173,780 | NCT06776367 | In-clinic study visits and clinic-collected specimens | Group A | null |
1,173,781 | NCT05504083 | take D-0120 dose 3 orally during the treatment period. | D-0120 group 3 | EXPERIMENTAL |
1,173,782 | NCT02398474 | Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block | iliac crest bone graft with a TFP block | EXPERIMENTAL |
1,173,783 | NCT02398474 | RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone | local anesthetic infiltration of the surgical site. | ACTIVE_COMPARATOR |
1,173,784 | NCT07172451 | Patients randomized to the balanced gelatin group will receive balanced gelatin solution (4% succinylated gelatin in a balanced crystalloid carrier) as the primary resuscitation fluid during emergency abdominal surgery for sepsis. Fluid administration follows a goal-directed protocol guided by strok | Balanced Gelatin Solution | EXPERIMENTAL |
1,173,785 | NCT07172451 | Patients randomized to the crystalloid group will receive acetate Ringer's solution as the sole resuscitation fluid during emergency abdominal surgery for sepsis, according to the same goal-directed protocol guided by stroke volume monitoring. No gelatin solution will be administered in this group. | Crystalloid Solution | ACTIVE_COMPARATOR |
1,173,786 | NCT07167966 | Intravenous infusions of anti-amyloid mAb-matched placebo for 6 months, followed by subcutaneous injections of AADvac1 over 24 months (n = 150) | AADvac1 monotherapy | EXPERIMENTAL |
1,173,787 | NCT07167966 | Intravenous infusions of an anti-amyloid mAb for 6 months, combination anti-amyloid mAb and subcutaneous injections of AADvac1 for 6 months, followed by 18 months of AADvac1 injections alone (n = 150) | Combination AADvac1 therapy with anti-amyloid monoclonal antibody (mAb) | EXPERIMENTAL |
1,173,788 | NCT07167966 | Intravenous infusions of an anti-amyloid mAb for 6 months, combination anti-amyloid mAb and AADvac1-matched placebo subcutaneous injections for 6 months, followed by 18 months of AADvac1-matched placebo injections alone (n = 75). | Anti-amyloid monoclonal antibody (mAb) active control | ACTIVE_COMPARATOR |
1,173,789 | NCT06778148 | Providers not assigned a license or waitlisted | Control | NO_INTERVENTION |
1,173,790 | NCT04598854 | The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 \~ 3.0Mw, 60 minutes each time, on | Treatment group | EXPERIMENTAL |
1,173,791 | NCT04598854 | The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity. | Control group | SHAM_COMPARATOR |
1,173,792 | NCT05636358 | "The intervention includes existing home-based hypnotherapy self-exercises in MP3 format for a period of three months.~The intervention group of children with FAP or IBS in primary care receives the home-based hypnotherapy self exercises in addition to care as usual by their GP according to the guid | Home-based hypnotherapy | EXPERIMENTAL |
1,173,793 | NCT05636358 | The control group of children with FAP or IBS in primary care will receive only care as usual by their GP. After the end of the study, the control group will also receive access to the home-based hypnotherapy exercises, if desired. | Control | NO_INTERVENTION |
1,173,794 | NCT06776367 | Fully remote evaluation and self-collected specimens | Group B | null |
1,173,795 | NCT07174310 | Participants will receive Prasinezumab as an IV infusion in the double blind treatment period. Upon completion, eligible participants will enter into the Open Label Extension (OLE) phase. | Prasinezumab | EXPERIMENTAL |
1,173,796 | NCT07174310 | Participants will receive placebo as an IV Infusion. | Placebo | EXPERIMENTAL |
1,173,797 | NCT07176559 | Eligible and consented patients randomly assigned to the spiritual care intervention will receive a total of 4 visits with a board-certified or board-eligible chaplain. The intervention will utilize the Spiritual Care Assessment and Intervention (SCAI) framework. These visits will occur weekly for a | Spiritual Care | EXPERIMENTAL |
1,173,798 | NCT07176559 | Eligible and consented patients randomly assigned to the Informational Support comparator will receive 4 visits with a trained social worker. The comparator intervention will include discussion of topics including quality of life, financial resources, and evaluating health information. These visits | Informational Support | PLACEBO_COMPARATOR |
1,173,799 | NCT04325646 | Subjects who had been to China in the weeks before the outbreak began | CORSER-1a | null |
1,173,800 | NCT06776458 | Breast cancer patients at 1-year post-diagnosis, who were treated with aromatase inhibitors | Aromatase Inhibitors (1 year) | null |
1,173,801 | NCT06776458 | Breast cancer patients at 5-year post-diagnosis, who were treated with aromatase inhibitors | Aromatase Inhibitors (5 year) | null |
1,173,802 | NCT06362369 | Alintegimod dose escalation, 4 cohorts Alintegimod monotherapy 1 cycle Alintegimod + Ipilimumab - 4 cycles Nivolumab - 11 cycles | Dose Escalation - Open Label Phase 1b | EXPERIMENTAL |
1,173,803 | NCT07171905 | null | investigating the role of CAIX as target in VHL disease and in VHL-/- tumors | EXPERIMENTAL |
1,173,804 | NCT07174440 | Participants scheduled for spinal surgery will have ESP block medications administered as per standard care along with contrast dye. | Spinal Surgery Participants | EXPERIMENTAL |
1,173,805 | NCT07177885 | Blood collection | Migraineurs responding to triptans | null |
1,173,806 | NCT07177885 | Blood collection | Migraine sufferers resistant to triptans | null |
1,173,807 | NCT07180147 | "Community-dwelling adults aged 50 and older who receive a comprehensive baseline and annual health assessment at the Marymount University Center for Optimal Aging. Assessments include physical, cognitive, and psychosocial measures. Results are compiled into a personalized Health Passport with tailo | ALOHA Health Passport Cohort | null |
1,173,808 | NCT07180550 | Participants will perform a high-intensity interval training based on six sets of 2-minute runs at an intensity of 90-95% of the maximal aerobic speed (MAS) on a treadmill. The recovery between each set will be 2 minutes, during which the subject will walk at an intensity of 50-60% of MAS. | High-intensity interval training (running) | EXPERIMENTAL |
1,173,809 | NCT07180550 | Participants will perform a high-intensity interval training based on six sets of 2-minute cycling will be performed at an intensity of 90-95% of the maximal heart rate on a stationary bike. The recovery between each set will be 2 minutes, during which the subject will cycle at an intensity of 50-60 | High-intensity interval training (cycling) | EXPERIMENTAL |
1,173,810 | NCT04662632 | Local antibiotic irrigation via the VT-X7 (Vancomycin and Tobramycin Exchanged over 7 Days) Treatment System adjuvant to two-stage exchange arthroplasty per standard of care. | Experimental | EXPERIMENTAL |
1,173,811 | NCT04662632 | Standard of care for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer. | Control | ACTIVE_COMPARATOR |
1,173,812 | NCT02571543 | "2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or | Intervention | EXPERIMENTAL |
1,173,813 | NCT02571543 | The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examinat | Control | NO_INTERVENTION |
1,173,814 | NCT06776458 | Breast cancer patients at 10-years post-diagnosis, who were treated with aromatase inhibitors | Aromatase Inhibitors (10 years) | null |
1,173,815 | NCT06776458 | A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible) | Matched Controls (1 year) | null |
1,173,816 | NCT07332546 | Participants receive bilateral ultrasound-guided external oblique intercostal block (EOIB) (15 mL of the study local anesthetic mixture per side) in addition to standard general anesthesia and standardized postoperative analgesia (IV PCA butorphanol ). | EOIB Group | EXPERIMENTAL |
1,173,817 | NCT07332546 | Participants do not receive any regional block. They receive standard general anesthesia and standardized postoperative analgesia only (IV PCA butorphanol). | Control Group | SHAM_COMPARATOR |
1,173,818 | NCT04325646 | Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020 | CORSER-1b | null |
1,173,819 | NCT06776458 | A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible) | Matched Controls (5 years) | null |
1,173,820 | NCT06776458 | A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible) | Matched Controls (10 years) | null |
1,173,821 | NCT05548088 | The subjects met the inclusion criteria, then collect the Lymphocytes and transfected with lentivirus to obtain LILRB4 STAR-T cells. The subjects were given fludarabine and cyclophosphamide chemotherapy 5 days before and 3 days after cell reinfusion. After two days of rest, the cells were reinjected | LILRB4 STAR-T cells | EXPERIMENTAL |
1,173,822 | NCT03684109 | Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain. | IDH-Mutant Glioma Patients | EXPERIMENTAL |
1,173,823 | NCT06301997 | ZAX.1400.P03, applied topically twice daily for 3 weeks after enrolment | Topical ZAX.1400.P03 | EXPERIMENTAL |
1,173,824 | NCT06301997 | Placebo, applied topically twice daily for 3 weeks after enrolment | Placebo | PLACEBO_COMPARATOR |
1,173,825 | NCT06465511 | Patients randomized to the intervention arm will attend a 120-minute survivorship clinic in which each participant will be assessed by members of a multidisciplinary team comprising an oncology nurse practitioner, a dietitian, a cancer exercise specialist, and a counsellor. | Supportive clinic | EXPERIMENTAL |
1,173,826 | NCT06465511 | Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations. | Control: Self-management | ACTIVE_COMPARATOR |
1,173,827 | NCT05320432 | Prior to the procedure, the patient will have two sets of two self-adhesive electrodes placed parallel to the spinal cord at the T10-L1 and S2-S4 levels for TENS administration. For participants randomized to the experimental group, the non-blinded study coordinator will turn on the TENS unit 5 minu | Transcutaneous electrical nerve stimulation (TENS) | EXPERIMENTAL |
1,173,828 | NCT05320432 | For the participants randomized to sham, the same placement of electrodes will occur, but the unit will not be delivering electrical stimulation. | Sham | SHAM_COMPARATOR |
1,173,829 | NCT04823611 | Placebo solution for subcutaneous injection. | Part A:Placebo | PLACEBO_COMPARATOR |
1,173,830 | NCT04823611 | AZD8233 for subcutaneous injection. | Part A:AZD8233 | EXPERIMENTAL |
1,173,831 | NCT04823611 | Placebo solution for subcutaneous injection. | Part B:Placebo | PLACEBO_COMPARATOR |
1,173,832 | NCT04823611 | AZD8233 medium dose for subcutaneous injection. | Part B:AZD8233 medium dose | EXPERIMENTAL |
1,173,833 | NCT04823611 | AZD8233 low dose for subcutaneous injection. | Part B:AZD8233 low dose | EXPERIMENTAL |
1,173,834 | NCT04823611 | Placebo solution for subcutaneous injection. | Part C: Placebo | PLACEBO_COMPARATOR |
1,173,835 | NCT04823611 | AZD8233 medium dose for subcutaneous injection. | Part C: AZD8233 medium dose | EXPERIMENTAL |
1,173,836 | NCT04767568 | "In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor" | Blood test | EXPERIMENTAL |
1,173,837 | NCT06300944 | At the beginning of the operation, intravenous infusion of reifentanil 0.1\~0.2 μg/kg·min, propofol 2\~4mg/kg·h, rocuronium 0.3mg/kg·h intermittently, inhalation of 1%\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate | Group C(Control Group) | ACTIVE_COMPARATOR |
1,173,838 | NCT01972555 | Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40. | Minimally invasive aortic valve replacement | EXPERIMENTAL |
1,173,839 | NCT04325646 | Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens | CORSER-2a | null |
1,173,840 | NCT04634903 | The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasiz | Supportive Therapy SSI (ST-SSI) | ACTIVE_COMPARATOR |
1,173,841 | NCT04634903 | The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identif | Behavioral Activation SSI (BA-SSI) | EXPERIMENTAL |
1,173,842 | NCT04634903 | "Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study sum | Growth Mindset SSI (GM-SSI) | EXPERIMENTAL |
Clinical Trials Knowledge Graph
7,628,735 nodes. 15,531,427 edges. 575,778 clinical trials registered on ClinicalTrials.gov — with their arms, outcomes, sites, sponsors, conditions, interventions, MeSH codes and linked PubMed publications.
Built with Samyama Graph. Loader and ETL: samyama-ai/clinicaltrials-kg.
Stored as Parquet — 623 MB, against roughly 7 GB as raw JSON.
Attribution — required
Two acknowledgements travel with this data:
Courtesy of the U.S. National Library of Medicine.
Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Clinical Trials Transformation Initiative (CTTI). Available at: https://aact.ctti-clinicaltrials.org/
Neither NLM nor CTTI endorses this dataset, its processing, or anything derived from it.
Licence
| Registry data | U.S. Government public domain (ClinicalTrials.gov, via AACT) |
| PubMed, MeSH | NLM terms — no fees or royalties, commercial use permitted |
| Loader code | Apache-2.0, in the GitHub repo. This does not govern the data. |
license: other is used deliberately rather than a convenient SPDX tag. No single standard
licence describes this: the underlying registry content is US Government material outside
copyright, while NLM and CTTI both request attribution, which CC0 would wrongly imply is
waived. The terms in full:
- NLM (terms) — "No charges, usage fees or royalties"; reuse including commercial is permitted; you must acknowledge NLM, must not suggest NLM endorses your work, and must either track the current version or state that your copy may be outdated. This copy is a snapshot of 2026-04-02 and is not updated — see Limitations.
- AACT / CTTI (site) — AACT is a daily reload of ClinicalTrials.gov: "Content is downloaded from ClinicalTrials.gov daily and loaded into AACT." CTTI states no licence and imposes no restriction, "encourages the use of all materials", and asks that the source be acknowledged, supplying the citation above.
What we checked, and what we did not. Both sets of terms above were read directly at source. Neither prohibits redistribution. CTTI publishes no formal licence grant, so the basis for redistributing the AACT-derived portion is that its content is US Government registry data outside copyright, plus CTTI's own encouragement to use it. That is an assessment from published terms, not legal advice.
⚠️ What was removed, and why
The upstream repository builds this graph from more sources than are published here. Two were excluded because their terms do not permit redistribution:
| Removed | Why | Nodes |
|---|---|---|
AdverseEvent |
Every record is MedDRA-coded (source_vocabulary: "MedDRA"). MedDRA is licensed by ICH/IFPMA on a paid subscription; its terminology may not be redistributed without one. FDA publishing FAERS does not transfer MedDRA's rights. |
145,711 |
Drug |
Every record carries a drugbank_id. DrugBank has tiered terms, some of which prohibit redistribution outright. |
5,256 |
150,967 nodes (1.9%) and 11,448,933 incident edges (42%) were removed. The edge count
falls far more than the node count because adverse-event reporting is dense — each trial
reports many events. The REPORTED and CODED_AS_DRUG edge types are therefore absent
entirely.
No .sgsnap snapshot is shipped with this dataset, unlike the others in this
organisation. The snapshot still contains the MedDRA and DrugBank records, so publishing it
would undo the exclusion.
If you need adverse-event or drug data, obtain it from MedDRA and DrugBank directly under their own terms, and rebuild with the ETL in the repository.
Files
Nodes carry an id; edges reference those ids as src and tgt.
nodes/
| File | Rows | Columns |
|---|---|---|
outcome.parquet |
3,564,582 | id, description, measure, time_frame, trial_nct_id, type |
armgroup.parquet |
1,055,533 | id, label, trial_nct_id, type |
site.parquet |
1,029,229 | id, city, country, facility |
publication.parquet |
750,114 | id, pmid, reference_type, title |
clinicaltrial.parquet |
575,778 | id, nct_id, title, official_title, brief_summary, phase, overall_status, study_type, enrollment, start_date, completion_date, primary_completion_date, has_results, why_stopped, last_updated |
intervention.parquet |
472,275 | id, description, name, type |
condition.parquet |
125,689 | id, name |
sponsor.parquet |
49,519 | id, class, name |
meshdescriptor.parquet |
6,016 | id, name |
edges/
| File | Rows | Connects |
|---|---|---|
measures.parquet |
3,564,582 | ClinicalTrial → Outcome |
conducted_at.parquet |
3,409,901 | ClinicalTrial → Site |
coded_as_mesh.parquet |
2,623,299 | Condition → MeSHDescriptor |
uses.parquet |
1,282,300 | ClinicalTrial → Intervention |
has_arm.parquet |
1,055,533 | ClinicalTrial → ArmGroup |
studies.parquet |
1,025,129 | ClinicalTrial → Condition |
published_in.parquet |
1,021,552 | ClinicalTrial → Publication |
tests.parquet |
973,353 | ArmGroup → Intervention |
sponsored_by.parquet |
575,778 | ClinicalTrial → Sponsor |
Usage
from datasets import load_dataset
trials = load_dataset("VaidhyaMegha/clinicaltrials-kg", "clinicaltrial", revision="v1.0")
print(trials["train"].num_rows) # 575778
Parquet reads well with anything columnar:
import pyarrow.parquet as pq
t = pq.read_table("nodes/clinicaltrial.parquet", columns=["nct_id", "phase", "overall_status"])
// Sponsors running the most trials
MATCH (t:ClinicalTrial)-[:SPONSORED_BY]->(s:Sponsor)
RETURN s.name, count(t) AS trials ORDER BY trials DESC LIMIT 5
// Conditions studied across the most countries — three hops, and the reason
// this is a graph rather than a set of tables
MATCH (c:Condition)<-[:STUDIES]-(t:ClinicalTrial)-[:CONDUCTED_AT]->(site:Site)
RETURN c.name, count(DISTINCT site.country) AS countries, count(DISTINCT t) AS trials
ORDER BY countries DESC LIMIT 10
Verification
- Node and edge totals reconcile against the snapshot header: 150,967 dropped + 7,628,735 written = 7,779,702; 11,448,933 dropped + 15,531,427 written = 26,980,360.
- 0 dangling edges — every
srcandtgtresolves to a node in this dataset. - 0 orphan nodes — despite removing 42% of edges, no node was left isolated.
- Distributions match the public registry: 439,465 interventional vs 134,313 observational (~76% interventional), and the highest-volume sponsors come out as Assiut University, Cairo University, GlaxoSmithKline, the National Cancer Institute and AP-HP — which is what ClinicalTrials.gov itself shows.
Limitations
- A 2026-04-02 snapshot, not a live mirror. ClinicalTrials.gov changes daily; NLM's terms require this to be stated. For current data go to the registry or AACT.
- No adverse events and no drug normalisation — see What was removed above. Any analysis of trial safety outcomes is out of scope for this dataset.
- Text fields are as-registered. Titles, summaries and outcome measures are sponsor-written free text, with the inconsistency that implies.
- Sites are facility strings, not geocoded or reconciled to any institution registry.
- Conditions and interventions are strings too;
CODED_AS_MESHgives partial normalisation for conditions only. - Registry data reflects what sponsors registered, which is not always what was conducted or published.
Not medical advice, and not a substitute for the official registry record.
Citation
Clinical Trials Knowledge Graph, v1.0 (7,628,735 nodes, 15,531,427 edges).
Built with Samyama Graph. https://huggingface.co/datasets/VaidhyaMegha/clinicaltrials-kg
ETL: https://github.com/samyama-ai/clinicaltrials-kg
Source data: ClinicalTrials.gov via the AACT database, Clinical Trials Transformation
Initiative (CTTI), https://aact.ctti-clinicaltrials.org/
Courtesy of the U.S. National Library of Medicine.
Snapshot date: 2026-04-02
The three pieces
| Piece | Where |
|---|---|
| Code — ETL, schema, loaders | github.com/samyama-ai/clinicaltrials-kg |
| Data — this dataset, and the registry it derives from | here, and aact.ctti-clinicaltrials.org |
| Graph — rebuild from these Parquet files with the ETL | (no snapshot shipped — see above) |
- Downloads last month
- 41